Versor Investments LP Grows Position in ICU Medical, Inc. (NASDAQ:ICUI)

Versor Investments LP increased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 210.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,118 shares of the medical instruments supplier’s stock after buying an additional 4,822 shares during the period. Versor Investments LP’s holdings in ICU Medical were worth $1,297,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ICUI. Allworth Financial LP increased its stake in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the last quarter. Xponance Inc. increased its stake in ICU Medical by 6.0% in the second quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after purchasing an additional 112 shares during the last quarter. Equitable Trust Co. increased its stake in ICU Medical by 2.2% in the third quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier’s stock valued at $950,000 after purchasing an additional 112 shares during the last quarter. CWM LLC increased its stake in ICU Medical by 18.5% in the second quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock valued at $91,000 after purchasing an additional 120 shares during the last quarter. Finally, Hexagon Capital Partners LLC increased its stake in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares during the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. KeyCorp increased their price target on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Raymond James increased their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.25.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,973,261.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $17,973,261.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,502 shares of company stock valued at $8,445,976. 6.70% of the stock is owned by company insiders.

ICU Medical Price Performance

ICU Medical stock opened at $178.27 on Tuesday. ICU Medical, Inc. has a one year low of $79.85 and a one year high of $188.53. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The business has a fifty day moving average of $175.56 and a two-hundred day moving average of $141.16. The company has a market cap of $4.35 billion, a P/E ratio of -61.05 and a beta of 0.66.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.